Orexigen and FDA Agree on New Study

February 6th, 2012 by MorganDowney Leave a reply »

Orexigen Therapeutics Inc. has announced that it has reached agreement with the Food and Drug Administration on a new protocol to test for adverse cardiac events for it obesity-fighting compound, Contrave. Orexigen Therapeutics, Inc. – Press Release